Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries has informed that it enclosed a copy of the press release by Sun Pharmaceutical Industries (together with its subsidiaries / affiliated companies, ‘Sun Pharma’) about ‘Phase 3 Clinical Studies Evaluating Tildrakizumab 100 mg (ILUMYA) in Active Psoriatic Arthritis Meet their Primary Endpoint’.

The above information is a part of company’s filings submitted to BSE.